Format

Send to

Choose Destination
Complement Ther Med. 2019 Aug;45:50-56. doi: 10.1016/j.ctim.2019.05.018. Epub 2019 May 18.

A multicenter study on the efficacy and safety of So-Cheong-Ryong-Tang for perennial allergic rhinitis.

Author information

1
Department of Ophthalmology, Otorhinolaryngology & Dermatology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. Electronic address: mhkim@khnmc.or.kr.
2
Department of Ophthalmology, Otorhinolaryngology & Dermatology, College of Korean Medicine, Dongguk University, Gyeongju, Republic of Korea. Electronic address: heenthsu@duih.org.
3
Department of Ophthalmology, Otorhinolaryngology & Dermatology, College of Korean Medicine, Semyung University, Jecheon, Republic of Korea. Electronic address: kht8725c@semyung.ac.kr.
4
Department of Ophthalmology, Otorhinolaryngology & Dermatology, College of Korean Medicine, Pusan National University, Pusan, Republic of Korea. Electronic address: aran99@pusan.ac.kr.
5
Department of Ophthalmology, Otorhinolaryngology & Dermatology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. Electronic address: kmdkskim@khu.ac.kr.
6
Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. Electronic address: epiko@khu.ac.kr.
7
Department of Ophthalmology, Otorhinolaryngology & Dermatology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. Electronic address: inhwajun@khnmc.or.kr.

Abstract

BACKGROUND:

So-Cheong-Ryong-Tang (SCRT), also known as Xiao-Qing-Long-Tang or Sho-seiryo-to, is a mixed herbal formula that is used to treat allergic rhinitis, bronchitis, allergic asthma, and common cold in traditional Korean medicine.

OBJECTIVE:

To assess the efficacy and safety of the SCRT for the treatment of allergic rhinitis.

METHODS:

We conducted a double-blind, randomized, placebo-controlled, parallel-group, multicenter study of Korean adults with perennial allergic rhinitis. The trial consisted of a 4-week oral administration of SCRT or placebo, with two visits at 2-week intervals, and an 8-week follow-up period, with two visits at 4-week intervals. The primary outcome was a change in the total nasal symptoms score. The secondary outcomes included changes in the Rhinoconjunctivitis Quality of Life Questionnaire score, total serum immunoglobulin E (IgE), cytokines levels, and nasal endoscopy index.

RESULTS:

SCRT improved nasal symptoms and quality of life in patients with PAR after 4 weeks medication, and these effects did not last 8 weeks after the end of medication. The level of serum IgE, eosinophil counts, and cytokines did not alter after medication. Nasal endoscopy index did not show significant difference. No serious AEs and safety assessment changes were observed in this trial.

CONCLUSION:

SCRT is an effective and safe medication for patients with chronic, perennial, and moderate to severe AR. A clinical study with a >4-week period of medication use, and more participants for immune material test is needed to investigate the long-term efficacy of SCRT in relieving the symptoms of nasal obstruction and identifying the underlying mechanisms of action and indications for traditional Korean medicine.

KEYWORDS:

Allergic rhinitis; Allergy; Herbal medicine; So-Cheong-Ryong-Tang; Xiao-Qing-Long-Tang

PMID:
31331582
DOI:
10.1016/j.ctim.2019.05.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center